Updated On: 30 September, 2021 07:08 AM IST | Washington | Agencies
The company has provided health regulators with data from recent study of its vaccine in children 5 to 11 years

An emergency medical technician, gives a second dose of the Pfizer-BioNTech COVID-19 vaccine to Aaron Delgado, 16, in Los Angeles on August 23. Pic/AFP
Pfizer has submitted research to the U.S Food and Drug Administration on the effectiveness of its Covid-19 vaccine in children but the shots may not be available until November.
The company said Tuesday it provided health regulators with data from a recent study of its vaccine in children 5 to 11 years old. Officials had said previously they would file an application with the FDA to authorize use in the coming weeks.